ReviewTherapeutic advances in neurological disorders2017
MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.
Review in Therapeutic advances in neurological disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Pooled it
- Magnetic resonance imaging-based biomarkers of multiple sclerosis and neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dysfunction (nLUTD): Over 20 Years' Experience and Future Directions.Advances in therapy · 2021Pooled it
- Role of Vitamin D in Preventing and Treating Selected Extraskeletal Diseases-An Umbrella Review.Nutrients · 2020Pooled it
- An Exposure-Response Analysis of the Clinical Efficacy of Ponesimod in a Randomized Phase II Study in Patients with Multiple Sclerosis.Clinical pharmacokinetics · 2021Trial
- Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis Episode.JAMA network open · 2020Trial
- Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGJournal of neurology, neurosurgery, and psychiatry · 2020Trial
- Neural Stem Cells in Multiple Sclerosis: A Comprehensive Review of Preclinical and Clinical Evidence for CNS Repair and Translational Hurdles.Applied biochemistry and biotechnology · 2026Review
- A Robust Dual-Stage Learning-Based Pipeline for Multiclass Segmentation of Multiple Sclerosis Lesions in MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Deep learning in imaging analysis for multiple sclerosis: Diagnosis and monitoring.Caspian journal of internal medicine · 2026Review
- Exploring the Association of Interleukin 13 Polymorphism (rs20541) and Serum Lipocalin 2 with Risk and Disability in Multiple Sclerosis.Journal of inflammation research · 2026Article
- Distinguishing pseudoprogression from true tumor growth after stereotactic surgery in vestibular schwannoma: a volumetric and clinical trajectory analysis.Radiation oncology (London, England) · 2025Article
- Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.International journal of molecular sciences · 2025Article
- Super-Resolution in Clinically Available Spinal Cord MRIs Enables Automated Atrophy Analysis.AJNR. American journal of neuroradiology · 2025Article
- Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study.Journal of clinical medicine · 2025Article
- Evaluation of two AI techniques for the detection of new T2/FLAIR lesions in the follow-up of multiple sclerosis patients.Frontiers in neurology · 2025Article
- Predicting multiple sclerosis prognosis using AI and machine learning: integrating clinical, immunological, and radiological variables.Frontiers in neurology · 2025Article
- Ultrafast Brain MRI at 3 T for MS: Evaluation of a 51-Second Deep Learning-Enhanced T2-EPI-FLAIR Sequence.Diagnostics (Basel, Switzerland) · 2024Article
- Revolutionizing Neurology: The Role of Artificial Intelligence in Advancing Diagnosis and Treatment.Cureus · 2024Review
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) has developed into the most important tool for the diagnosis and monitoring of multiple sclerosis (MS). Its high sensitivity for the evaluation of inflammatory and neurodegenerative processes in the brain and spinal cord has made it the most commonly used technique for the evaluation of patients with MS. Moreover, MRI has become a powerful tool for treatment monitoring, safety assessment as well as for the prognostication of disease progression. Clinically, the use of MRI has increased in the past couple decades as a result of improved technology and increased availability that now extends well beyond academic centers. Consequently, there are numerous studies supporting the role of MRI in the management of patients with MS. The aim of this review is to summarize the latest insights into the utility of MRI in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.